Login
$PCRX
$36.49 +$0.02 (0.07%) Live

$PCRX 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Regulation FD Disclosure

As previously disclosed, pursuant to an agreement entered into between the Research Development Foundation (“RDF”) and a wholly-owned subsidiary of Pacira BioSciences, Inc. (the “Company” or “Pacira”), the Company was required to pay RDF...

05 Nov 2026 8-K: Regulation FD Disclosure

As previously disclosed, on October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company” or “Pacira”), entered into the Agreement and Plan of Merger (the “Merger Agreement”) with Viatris Inc., a Delaware corporation (...

08 Oct 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of October 8, 2026 (the “Agreement Date”), by and among Viatris Inc., a Delaware corporation (“Parent”), Peach Purchaser Sub Inc., a Delaware corporation an...

04 Aug 2026 8-K: Results of Operations and Financial Condition

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships --

30 Jun 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments --

11 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more

The purposes of the Amended and Restated 2014 Employee Stock Purchase Plan (the “Plan”) are to (a) assist qualified employees of the Company, and its Designated Subsidiaries in acquiring a stock ownership interest in the Company and (b) ...

30 Apr 2026 8-K: Results of Operations and Financial Condition

-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent --

26 Feb 2026 8-K: Results of Operations and Financial Condition

— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years —

28 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise --

08 Jan 2026 8-K: Results of Operations and Financial Condition

-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years--

06 Nov 2025 8-K: Results of Operations and Financial Condition

-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% --

05 Aug 2025 8-K: Results of Operations and Financial Condition

-- Solid execution across corporate, clinical and commercial initiatives --

10 Jul 2025 8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure

On July 10, 2025, Pacira BioSciences, Inc. sent the following note to employees:

07 Jul 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

as Administrative Agent, Swingline Lender and an Issuing Bank

13 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The purpose of this Amended and Restated 2011 Stock Incentive Plan (the “Plan”) of Pacira BioSciences, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s abi...

08 May 2025 8-K: Results of Operations and Financial Condition

BRISBANE, CA, May 8, 2025 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the firs...

22 Apr 2025 8-K: Other Events

On April 17, 2025, Pacira BioSciences, Inc. (the “Company”) announced that its Board of Directors has approved a new share repurchase program, effective immediately, which authorizes the Company to purchase up to an aggregate of $300.0 m...

07 Apr 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

-- Fresenius Kabi licensed to sell volume-limited amounts of generic liposomal bupivacaine in the U.S. beginning on a confidential date in 2030 --

14 Mar 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

1.1 Place of Meetings. All meetings of stockholders shall be held at such place as may be designated from time to time by the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the President or, if not so desig...

27 Feb 2025 8-K: Results of Operations and Financial Condition

— Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million —

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support